Gail Farfel
Director/Board Member bei DURECT CORPORATION
Vermögen: 117 517 $ am 31.03.2024
Profil
Gail M.
Farfel is currently a Director at DURECT Corp., PrintedArt, FAAH Pharma, Inc., Avrobio, Inc., and the American Society For Experimental Neurotherapeutics.
Previously, she held positions as the President, Chief Executive Officer & Director at ProMIS Neurosciences, Inc., Senior Associate Director at Pfizer Inc., Director at Zogenix International Ltd., Chief Clinical & Regulatory Officer at Marinus Pharmaceuticals, Inc., VP-Therapeutic Area & Head-Neuroscience at Novartis Pharmaceuticals Corp., and Global Team Lead at Pfizer Pharmaceuticals, Inc. She also served as the President of G Meredith Consulting LLC.
Dr. Farfel obtained her undergraduate degree from the University of Virginia and her doctorate from The University of Chicago.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 23.08.2023 | 55 192 ( 0,29% ) | 105 417 $ | 31.03.2024 | |
DURECT CORPORATION
0,03% | 26.03.2024 | 10 000 ( 0,03% ) | 12 100 $ | 31.03.2024 |
AVROBIO INC
-.--% | 07.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Gail Farfel
| Unternehmen | Position | Beginn |
|---|---|---|
| DURECT CORPORATION | Director/Board Member | 25.04.2019 |
| AVROBIO, INC. | Director/Board Member | 21.10.2020 |
PrintedArt
 PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Director/Board Member | - |
| American Society For Experimental Neurotherapeutics | Director/Board Member | - |
FAAH Pharma, Inc.
 FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Director/Board Member | 07.08.2014 |
Ehemalige bekannte Positionen von Gail Farfel
| Unternehmen | Position | Ende |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Chief Executive Officer | 30.12.2023 |
| ZOGENIX, INC. | Corporate Officer/Principal | 01.09.2022 |
| MARINUS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2015 |
| G Meredith Consulting LLC | President | 01.12.2012 |
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Gail Farfel
| University of Virginia | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| PFIZER, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Pfizer Pharmaceuticals, Inc.
 Pfizer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products. | Health Technology |
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
PrintedArt
PrintedArt Other Consumer ServicesConsumer Services PrintedArt provides photography and printing services. | Consumer Services |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Health Technology |
| G Meredith Consulting LLC | |
| American Society For Experimental Neurotherapeutics |
